Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug (Naltrexone, Buprenorphine, Methadone), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Opioid Use Disorder Market Size & Trends

The global opioid use disorder market size was valued at USD 4.59 billion in 2023 and is projected to grow at a CAGR of 11.65% from 2024 to 2030. The expansion of the market is driven by the rising rates of substance use disorders, growing government efforts to address the crisis, and increased awareness of opioid use disorder treatments. These factors are anticipated to significantly boost market growth over the forecast period, fostering innovation and improving access to addiction care solutions.

The rising incidence of substance use disorders is a major factor driving the market for medications targeting conditions like opioid use disorder. As more individuals experience substance use issues, the demand for effective treatments grows, shaping market trends and stimulating advancements in addiction medicine. The 2022 National Survey on Drug Use and Health (NSDUH), published by the Substance Abuse and Mental Health Services Administration (SAMHSA), offers extensive data on substance use and mental health trends in the U.S. According to the survey, 59.8% of individuals aged 12 or elder engaged in the use of tobacco, alcohol, or illicit drugs in 2022, with 70.3 million having used illicit drugs within the past year, and marijuana being the most frequently used. Additionally, 48.7 million people were reported to have a substance use disorder (SUD), encompassing both alcohol and drug use disorders. The survey also found that 23.1% of adults experienced mental illness, and 19.5% of adolescents had a major depressive episode.

Furthermore, increasing government efforts are becoming key factors in the opioid use disorder market, as they boost awareness, accessibility, and affordability of addiction treatment globally. These efforts focus on broadening access to treatment and recovery services, improving public health measures, and intensifying law enforcement actions to curb illegal drug availability. They also stress the importance of education and awareness campaigns to avert substance misuse and encourage safe prescribing practices among healthcare professionals.

Additionally, these initiatives involve enhancing collaboration among federal, state, and local authorities and integrating evidence-based approaches to tackle the multifaceted issues of opioid addiction in communities nationwide. For instance, in February 2023, in response to the ongoing opioid overdose crisis, the FDA outlined a comprehensive strategy. This includes implementing recommendations from the 2017 NASEM Report, enhancing transparency in opioid analgesic decision-making, and seeking additional congressional authorities. The FDA's Overdose Prevention Framework emphasizes evidence generation through initiatives such as the SOURCE simulation model and advisory committee meetings to evaluate long-term opioid efficacy.

In June 2024, an NIH-funded survey revealed significant public unawareness regarding primary care physicians' ability to prescribe medications for OUD, with 61% unaware and 13% holding incorrect beliefs. Targeted campaigns and integrating OUD treatment into primary care settings are recommended to bridge this knowledge gap and improve access to lifesaving medications. The survey suggests a potential market opportunity for pharmaceutical companies and healthcare providers to enhance education & integration efforts, thereby increasing demand for OUD treatments in primary care settings.

Moreover, with recent developments and funding allocations, the OUD market is poised for significant shifts, driven by both governmental initiatives and emerging public health insights. For instance, on International Overdose Awareness Day in August 2023, the Biden-Harris administration announced over USD 450 million to combat the overdose epidemic, enhance prevention, treatment, and recovery services, and curb illicit drug trafficking. Initiatives include expanding CDC's OD2A grants, funding drug-free communities, and supporting rural communities with naloxone distribution & behavioral healthcare access.

Market Concentration & Characteristics

The market is innovating with new medications, long acting injectables, digital health tools, personalized treatments, integrated behavioral therapies, harm reduction strategies, and ongoing research, improving treatment efficacy, accessibility, and overall management of the disorder. For instance, in September 2023, Camurus AB has introduced Brixadi, a medication available in weekly and monthly formulations containing buprenorphine, designed to treat moderate-to-severe opioid use disorder (OUD). Patients currently on daily buprenorphine therapy or those beginning treatment with a single dose of transmucosal buprenorphine qualify for this regimen.

Several players engage in mergers & acquisitions to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve competency. For instance, in March 2023, Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc., intending to improve the treatment of opioid addiction or overdose. This acquisition was anticipated to strengthen the company's position in the market.

Regulatory measures play a crucial role in shaping the growth and development of opioid use disorder (OUD) treatments by ensuring safety, efficacy, and quality. These regulations help build confidence among healthcare providers and patients. However, stringent regulations can also pose barriers to access and raise costs, potentially impacting affordability and market dynamics. Regulatory frameworks encourage innovation in drug formulations and combination therapies, aiming to improve treatment outcomes and minimize misuse risks. Striking a balance between regulatory oversight and accessibility is essential for maximizing the effectiveness of these treatments in combating opioid addiction.

In addition to FDA-approved medications like buprenorphine, methadone, and naltrexone, several other therapies are used to manage OUD. Counseling and behavioral therapies, including cognitive-behavioral therapy and contingency management, support medication-based treatment. Opioid overdose reversal medications such as naloxone and nalmefene are crucial for emergency intervention. Off-label medications like clonidine, lofexidine, gabapentin, and pregabalin can help manage withdrawal symptoms and cravings, though evidence for their effectiveness in OUD is limited compared to the primary treatments. A comprehensive approach integrates these therapies for optimal recovery outcomes. communicate the unique benefits of opioid use disorder in opioid use disorder treatment.

The market is set for substantial regional growth, driven by the global need to address the increasing prevalence of OUD. This underscores the critical role of regional strategies in the development and delivery of effective treatments. For instance, in May 2024, Novo Nordisk acquired Alkermes plc.'s development and production facilities in Athlone, Ireland, for USD 91 million. Alkermes's Wilmington, Ohio-based manufacturing plant would continue producing its exclusive commercial products, ARISTADA, VIVITROL, ARISTADA INITIO, and LYBALVI.

Drug Insights

Buprenorphine led the market and accounted for 55.94% of the global revenue in 2023 due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk. Its ceiling effect reduces overdose risk, and when combined with naloxone, it further deters abuse. Buprenorphine’s versatility in forms like sublingual tablets and extended-release injectables enhances patient convenience and adherence. Unlike methadone, it doesn’t require daily clinic visits, making treatment more accessible. Its proven efficacy in reducing opioid use and supporting recovery solidifies its prominent role in OUD treatment.

Naltrexone segment held the second largest revenue share of the market in 2023 due to its unique advantages. As a full opioid antagonist, naltrexone effectively blocks opioid receptors, preventing relapse by eliminating the euphoric effects of opioids. Its long-acting injectable form, Vivitrol, offers convenience with monthly dosing, improving patient adherence and reducing the risk of relapse. Naltrexone’s non-addictive nature and lack of abuse potential enhance its appeal compared to other treatments. Additionally, increasing awareness and expanding insurance coverage are likely to drive its adoption, contributing to its rapid market growth.

Distribution Channel Insights

Hospital pharmacies dominated the market with a market share of 48.27% in 2023 due to their integral role in managing complex and severe cases. They offer a controlled environment where medications can be administered under strict supervision, which is crucial for ensuring adherence and safety, particularly for injectable and high-risk treatments. Hospital pharmacies also provide comprehensive patient care, including counseling and monitoring, which enhances treatment efficacy and supports recovery. Their ability to manage and distribute specialized medications, such as methadone and extended-release formulations, and their capacity for coordinating care with other healthcare services, solidify their dominant role in the distribution of OUD treatments. This central role in patient management and safety drives their prominence in the distribution channel.

Retail pharmacies are projected to witness a significant growth rate over the forecast period. Retail pharmacies play a crucial role in treating opioid use disorder (OUD) by making medications like naltrexone and buprenorphine readily available. Their convenient locations enable patients to easily fill prescriptions, while their counseling services help ensure treatment adherence. These pharmacies are essential to public health efforts aimed at addressing the opioid crisis, as their accessibility and community reach are key to improving treatment access and patient outcomes in OUD care.

Route of Administration Insights

The injectable segment dominated the market and accounted for 55.79% of the global revenue in 2023. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse. These formulations require less frequent administration typically monthly compared to daily oral medications, which enhances patient convenience and engagement. Injectable treatments also eliminate the risk of medication misuse or diversion, as they are administered by healthcare professionals. Additionally, the growing emphasis on patient-centered care and innovations in drug delivery systems are driving the adoption of injectables, positioning them as a rapidly expanding segment in OUD therapy.

The oral segment held the second largest revenue share in 2023. It is the most convenient and non-invasive method, which increases patient adherence and compliance. Oral medications such as buprenorphine and naltrexone are easier to administer and manage, requiring no specialized equipment or procedures. They also allow for flexible dosing and straightforward integration into daily routines. Additionally, oral medications can be taken at home, reducing the need for frequent clinic visits, thus improving accessibility and patient comfort. The established track record of oral formulations in effectively managing OUD, combined with their broad availability and ease of use, solidifies their leading position in the treatment landscape.

Regional Insights

North America opioid use disorder market accounted for 69.18% share in 2023 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions. North America benefits from advanced healthcare infrastructure, extensive research and development capabilities, and a well-established network of healthcare providers and treatment facilities. Additionally, robust regulatory frameworks and substantial funding for addiction treatment programs support the development and distribution of effective therapies. The presence of leading pharmaceutical companies and a strong focus on innovative treatment approaches further contribute to North America's leadership in the OUD treatment market.

U.S. Opioid Use Disorder Market Trends

The opioid use disorder market in the U.S. is experiencing substantial growth due to increased awareness among healthcare professionals about available treatments and a rise in the prevalence of the disease. The CDC reports that over 131,778,501 opioid prescriptions were dispensed in the U.S. in 2022, with approximately 145,000 new OUD diagnoses that year.

Europe Opioid Use Disorder Market Trends

The opioid use disorder market in Europe is undergoing significant transformation, driven by healthcare reforms, research advancements, and patient-centered initiatives across various countries. The rising prevalence of OUD, fueled by an aging population and evolving lifestyles, is increasing the demand for effective and innovative treatment options throughout the continent.

The UK opioid use disorder market is experiencing growth due to the rising prevalence of substance use disorders and expanding government initiatives to address the crisis. In the UK, over 50% of individuals with OUD are actively receiving treatment, with most undergoing Medications for Opioid Use Disorder (MOUD) such as methadone, buprenorphine, or naltrexone in 2023.

The opioid use disorder market in France is poised for growth due to increasing awareness, government support, and evolving treatment options. As France addresses rising OUD prevalence with enhanced healthcare policies and expanded access to effective therapies, the market is set to expand significantly, driven by these supportive factors.

Germany opioid use disorder market is marked by comprehensive treatment strategies and robust healthcare infrastructure. Enhanced by progressive regulations and increased funding for addiction services, Germany’s focus on integrated care and innovative therapies is driving significant growth and improving outcomes for individuals with opioid use disorder.

Asia Pacific Opioid Use Disorder Market Trends

The opioid use disorder market in Asia Pacific is growing due to rising awareness, expanding healthcare infrastructure, and increasing prevalence of OUD. Countries in the region are implementing enhanced treatment programs and government initiatives to address the crisis. Improved access to effective therapies and ongoing research are driving market expansion. Additionally, growing collaborations between international and local organizations are fostering innovation and better management strategies, contributing to the accelerated development of the market and improved patient outcomes across the Asia Pacific region.

The China opioid use disorder market is growing at a rapid pace due to increasing awareness, expanding healthcare initiatives, and rising OUD cases. Enhanced treatment options and government support are driving market expansion, alongside efforts to improve access to effective therapies and address the growing demand for comprehensive addiction care.

The opioid use disorder market in Japan is driven by rising awareness of addiction issues, government initiatives to improve treatment access, and advancements in healthcare infrastructure. Japan's focus on integrating innovative therapies and expanding support services is driving market growth. Additionally, efforts to address the increasing prevalence of OUD contribute to the market's expansion.

Latin America Opioid Use Disorder Market Trends

The opioid use disorder market in Latin America is expanding due to growing awareness, increased government and NGO support, and advancements in treatment options. Rising opioid abuse and the need for effective therapies are driving market growth. Enhanced access to medications and improved healthcare initiatives across the region are further contributing to the market’s development.

Brazil opioid use disorder market is significantly growing due to rising opioid abuse, increased government funding, and enhanced treatment programs. Expanded access to effective therapies and heightened awareness are driving this growth, alongside improved healthcare infrastructure and support services across the country.

Middle East & Africa (MEA) Opioid Use Disorder Market Trends

The opioid use disorder market in the Middle East & Africa (MEA) is expanding due to increasing awareness, government initiatives, and improved access to treatment. Rising opioid use and the development of healthcare infrastructure are driving growth, along with efforts to enhance support services and treatment options in the region.

Saudi Arabia opioid use disorder market is poised to grow due to rising awareness, government initiatives, and enhanced healthcare services. Efforts to improve treatment access and expand support for addiction recovery are driving market expansion, alongside increased focus on effective therapies and integrated care solutions in the region.

Key Opioid Use Disorder Company Insights

Some of the leading players operating in the opioid use disorder market include Alkermes plc., Orexo AB, Indivior PLC and Camurus among others. These players dominate the market with their contributions to the development of new treatments. BioCorRx, Inc., Braeburn, Inc., Delpor, Inc. are some of the emerging market participants in the opioid use disorder market. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel product launches to capitalize on untapped avenues. 

Recent Developments

• In July 2023, Titan Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with Fedson, Inc. As part of this deal, Titan agreed to sell a portion of its ProNeura assets, including its portfolio of addiction treatment medications and other early-stage projects based on the ProNeura drug delivery technology. This portfolio included implant programs for Nalmefene and Probuphine.

• In August, Alkermes plc and Teva Pharmaceuticals USA, Inc. reached a settlement agreement to conclude the parties' continuing patent action pertaining to VIVITROL (naltrexone for extended-release injectable suspension) in the U.S. District Court for the District of New Jersey.

• In March 2023, Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc., intending to improve the treatment of opioid addiction or overdose. This acquisition was anticipated to strengthen the company's position in the market. 

Opioid Use Disorder Market Report Scope

Global Opioid Use Disorder Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global opioid use disorder market report based on drug, route of administration, distribution channel and region.

• Drug Outlook (Revenue, USD Million, 2018 - 2030)

  • Naltrexone

  • Buprenorphine

    • BELBUCA

    • Sublocade

    • Suboxone

    • Zubsolv

    • Others

  • Methadone

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral Administration

  • Injectable Administration

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • Kuwait

    • UAE